drugset / Trial / NCT02820883
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Phase 0
Completed
30 enrolled
Jiangsu Province Centers for Disease Control and Prevention
Chengdu Olymvax Biopharmaceuticals Inc. · collabThird Military Medical University · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine.
Timeline
- Start
- 2016-06
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Staphylococcus aureus vaccine | Vaccine | 15 ug | — |
| Subject | Staphylococcus aureus vaccine | Vaccine | 30 ug | — |
| Subject | Staphylococcus aureus vaccine | Vaccine | 60 ug | — |